On Thursday, May 2, 2024, Pfizer shared a Community Letter announcing that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to fordadistrogene movaparvovec, Pfizer’s investigational gene therapy in development for the treatment of Duchenne muscular dystrophy.
Please click here to view the Community Letter.
